TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Video with JACC Editor Harlan Krumholtz offering an overview of key tricuspid and TAVR late-breakers at TCT24.

Progress in tricuspid valve care and TAVR on full display at TCT 2024

Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific TAVR valve comes up short in comparison with Medtronic, Edwards devices

The Acurate neo2 TAVR valve has been used to treat severe aortic stenosis in other parts of the world for years. In the United States, however, the device has still not been approved for commercial use.  

Didier Tchetche, MD, an interventional cardiologist and head of the structural heart disease program at Clinique Pasteur in Toulouse, France, and colleagues combined data from the RHEIA and PARTNER 3 trials into a single comparison of TAVR outcomes in female patients.

TAVR linked to better outcomes than surgery for women, pooled analysis confirms

New research presented at TCT combined data from the RHEIA and PARTNER 3 trials. “TAVR is a good option, and probably the best one, for an elderly woman," cardiologist Anna Sonia Petronio, MD, explained during the conference. 

EARLY TAVR investigator Philippe Généreux, MD, announced his team’s findings in front of a packed audience at TCT 2024.

Treating asymptomatic aortic stenosis with TAVR linked to significant benefits

Attendees cheered as lead investigator Philippe Généreux, MD, shared his team's findings at TCT 2024. “A major reset in our approach to severe asymptomatic AS is now warranted,” one veteran cardiologist said about the data. “The concept of watchful waiting is no longer appropriate."

Medtronic Evolut FX+ TAVR

Medtronic’s next-generation TAVR device receives CE mark approval

The Evolut FX+ TAVR system, which already received FDA approval in March, was designed with improved coronary access in mind. One cardiologist described the device as a "significant step forward" for patients with heart disease. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR survival is down in recent years, leaving cardiologists stumped

Researchers tracked recent TAVR data from the STS/ACC TVT Registry, highlighting a "concerning" finding they were unable to explain.

Thumbnail

Predicting vascular complications during TAVR just got a little easier

A new risk score shows potential to help cardiologists predict the risk of some TAVR complications before they happen, guiding important treatment decisions.

Performing transcatheter aortic valve replacement (TAVR) with the J-Valve transcatheter heart valve (THV) may help limit the risk of coronary artery obstruction (CAO) in high-risk patients, according to a new study published in Clinical Interventions in Aging.[1]

New-look TAVR valve recently acquired by Edwards may reduce risk of coronary obstruction

Early data suggest the J-Valve transcatheter heart valve could help care teams avoid a rare, but often fatal TAVR complication when treating high-risk patients. 

Displaying 25 - 32 of 419
Design by Adaptive Theme